Kura Oncology Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript
Good afternoon and welcome once again to Cowen's Third Annual Oncology Innovation Summit. I'm Phil Nadeau, one of Cowen's biotech analysts. It's my pleasure to next moderate a fireside chat with Troy Wilson, the President and CEO of Kura Oncology.
Questions & Answers
Troy, there's a lot of focus on ziftomenib and the upcoming data. Could you maybe begin by providing a brief review of the efficacy and safety data from ziftomenib's KOMET-001 trial that have already been presented?
Sure, Phil. And thank you to you and Cowen for the opportunity to participate in the summit. It's our pleasure. So ziftomenib has been in the Phase 1 and is currently in a Phase 1b -- excuse me -- Phase 1a/Phase 1b. The takeaways from the Phase 1a were good safety and tolerability, evidence of activity in the genetically selected populations. But because we were in an unselected
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
